ALLO stock forecast
Our latest prediction for Allogene Therapeutics, Inc.'s stock price was made on the Oct. 15, 2020 when the stock price was at 39.57$.
In the short term (2weeks), ALLO's stock price should underperform the market by -2.14%. During that period the price should oscillate between -10.06% and +8.59%.
In the medium term (3months), ALLO's stock price should underperform the market by -4.25%. During that period the price should oscillate between -34.69% and +21.36%.Get email alerts
Create a solid portfolio with ALLO
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.12$ per share.
The book value per share is 5.61$
Three months stock forecastOct. 15, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|